Cytokine-induced killer (CIK) cells, NK cells, CD8+ T cells, and γδ T-cells |
Targeting CSCs |
Ideal for BCSCs [90]; promotes specific elimination [91] |
DC-based vaccines |
Targeting CSCs |
Specifically targets BCSCs [93]; promotes specific elimination |
Adoptive T-cell therapy |
TIL isolation, culturing, and reinfusion |
Enhances antitumor immunity through T-cell activation [92] |
Oncolytic virotherapy (OVT) |
Immunogenic cell death and T-cell activation |
Induces antitumor immunity via immunogenic cell death [92] |
Combination with other immunotherapies |
Various immunotherapies combined |
Synergistic effect utilizing oncolytic viruses, DC-based vaccines, and checkpoint blockades |